Firms

Catalys Pacific

Catalys Pacific is an independent life-sciences venture capital firm and company builder operating across Japan and the United States. Catalys Pacific, LLC was established in 2018 and publicly launched its first fund inJune 2019. The firm combines local sourcing, scientific expertise and transpacific partnerships to form and finance biotechnology companies: advancing Japanese discoveries into global development and bringing overseas therapies into development and commercialization in Japan. Its activities include neuroscience and neuropsychiatry through creations such as Arialys, Aculys and Transposon. The firm is independently governed; its pharmaceutical strategic partners are limited partners, not a parent pharmaceutical company. Named vehicles include Catalys Pacific Fund, LP, Fund II and a Post-POC Fund for follow-on investment in clinical proof-of-concept companies. Its public roster includes investment professionals, operating partners and advisers.

Founded: —
Type: Venture capital

Funds3

Catalys Pacific Fund II, LP——
Life-sciences venture capital and company creation fund managed by Catalys Pacific, LLC. Japan Investment Corporation announced an LP investment agreement on July6,2022; this is an LP announcement rather than evidence of a fund final closing or total fund size.
Catalys Pacific Fund, LP——
First life-sciences venture and company creation fund of Catalys Pacific, publicly launched on June17,2019. Reviewed issuer release verifies the vehicle and strategy but does not disclose a final closed fund size. Exact legal name confirmed by institutional LP Japan Investment Corporation.
Catalys Pacific Post-POC Fund, LP——
Established in2022 to support drug discovery companies from existing Catalys funds after clinical proof of concept, funding late-stage development and commercialization. Japan Investment Corporation announced a USD14M LP investment on May15,2025; that commitment is not the total size of the fund, which remains unasserted.